|
Re: Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
|
6
|
Resverlogix Corp.
|
Sep 28, 2022 04:22PM
|
|
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
|
3
|
Resverlogix Corp.
|
Sep 28, 2022 04:20PM
|
|
Gilead's GS-5829 flops in mCRPC
|
10
|
Zenith Epigenetics
|
Jul 13, 2022 11:03AM
|
|
Re: Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jun 21, 2022 08:08AM
|
|
Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jun 21, 2022 08:08AM
|
|
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
|
5
|
Zenith Epigenetics
|
Jun 21, 2022 08:03AM
|
|
Re: New insights from this study -- Questions for scientists.
|
4
|
Resverlogix Corp.
|
Jun 08, 2022 12:18PM
|
|
Re: New insights from this study -- Questions for scientists.
|
10
|
Resverlogix Corp.
|
Jun 08, 2022 12:06PM
|
|
Re: RVX ANNOUNCES TYPE C MEETING WITH FDA FOR CORAL, A PHASE 3 HIGH-RISK COVID-19 OUTPATIENT STUDY
|
9
|
Resverlogix Corp.
|
May 10, 2022 12:26PM
|
|
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
|
6
|
Zenith Epigenetics
|
May 10, 2022 12:08PM
|
|
New Apabetalone Fabry Disease Publication
|
9
|
Resverlogix Corp.
|
Apr 26, 2022 07:27AM
|
|
Re: Finally some news
|
3
|
BIOASIS TECHNOLOGIES INC
|
Apr 11, 2022 04:31PM
|
|
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
|
7
|
Resverlogix Corp.
|
Mar 17, 2022 08:12AM
|
|
Re: Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
|
3
|
Resverlogix Corp.
|
Jan 18, 2022 10:51AM
|
|
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
|
3
|
Resverlogix Corp.
|
Jan 18, 2022 10:50AM
|
|
Re: Screening/NR Tmr morn Dosing has begun?
|
6
|
Resverlogix Corp.
|
Dec 19, 2021 05:18PM
|
|
Re: Risk vs Reward moving forward!
|
14
|
Resverlogix Corp.
|
Dec 18, 2021 07:56AM
|
|
Re: Risk vs Reward moving forward!
|
8
|
Resverlogix Corp.
|
Dec 17, 2021 02:32PM
|
|
Re: Update
|
9
|
Resverlogix Corp.
|
Dec 17, 2021 02:30PM
|
|
Re: COVID-19 and BRD4: a stormy and cardiotoxic bromo-romance
|
7
|
Resverlogix Corp.
|
Dec 14, 2021 01:53PM
|
